SGH
VRTX icon

Schonfeld Group Holdings’s Vertex Pharmaceuticals VRTX Stock Holding History

Schonfeld Group Holdings’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,500
Closed -$237K – 37
2014
Q2 		$237K Sell
2,500
-1,494
-37% -$105K 0.81% 17
2014
Q1 		$282K Buy
+3,994
New +$316K 0.07% 395

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Schonfeld Group Holdings's VRTX Position: Q3 2014 in Review

Schonfeld Group Holdings sold out of Vertex Pharmaceuticals (VRTX) in Q3 2014, closing a stake of 2,500 shares — an estimated $237K sold.

Schonfeld Group Holdings first reported a position in VRTX in Q1 2014 and held it in 2 quarters. The position peaked at $282K in Q1 2014. 430 funds tracked by Wall St. Rank hold VRTX as of Q3 2014.

  • Schonfeld Group Holdings reported no remaining Vertex Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Schonfeld Group Holdings sold 2,500 Vertex Pharmaceuticals shares in Q3 2014, an estimated $237K.
  • Schonfeld Group Holdings first reported a position in Vertex Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Schonfeld Group Holdings's Vertex Pharmaceuticals position peaked at $282K in Q1 2014.
  • 430 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2014.

Based on Schonfeld Group Holdings's 13F filing for Q3 2014, filed 17 Nov 2014.